Published in J Biol Chem on May 20, 2004
To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest (2008) 3.05
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2012) 1.75
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat (2008) 1.39
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell (2004) 1.22
ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis (2012) 1.09
Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One (2011) 1.05
Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ (2011) 1.04
Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol (2010) 1.04
Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res (2011) 1.02
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med (2011) 0.99
Andrographolide: a new plant-derived antineoplastic entity on horizon. Evid Based Complement Alternat Med (2011) 0.98
Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L). Cell Death Dis (2014) 0.98
Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget (2013) 0.97
Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic Biol Med (2012) 0.95
Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Exp Cell Res (2006) 0.94
Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia (2005) 0.92
F-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway. Cell Death Differ (2011) 0.92
Molecular targets of TRAIL-sensitizing agents in colorectal cancer. Int J Mol Sci (2012) 0.91
The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol Ther (2009) 0.89
Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle (2012) 0.89
Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer (2005) 0.88
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am J Cancer Res (2011) 0.88
A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. Proc Natl Acad Sci U S A (2015) 0.86
Targeting apoptosis signaling pathways for anticancer therapy. Front Oncol (2011) 0.85
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. Am J Clin Exp Immunol (2013) 0.84
TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br J Cancer (2006) 0.83
ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer. Cancer Biol Ther (2015) 0.81
FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells. Oncotarget (2015) 0.78
Activated Cdc42-associated kinase 1 (Ack1) is required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor recruitment to lipid rafts and induction of cell death. J Biol Chem (2013) 0.78
Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer. Cell Mol Life Sci (2016) 0.78
An RNA interference screen identifies new avenues for nephroprotection. Cell Death Differ (2015) 0.77
Eupafolin enhances TRAIL-mediated apoptosis through cathepsin S-induced down-regulation of Mcl-1 expression and AMPK-mediated Bim up-regulation in renal carcinoma Caki cells. Oncotarget (2016) 0.77
Gomisin N enhances TRAIL-induced apoptosis via reactive oxygen species-mediated up-regulation of death receptors 4 and 5. Int J Oncol (2011) 0.77
Parthenolide Sensitizes Human Colorectal Cancer Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand through Mitochondrial and Caspase Dependent Pathway. Intest Res (2014) 0.77
5,7-Dihydroxyflavone Enhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related Proteins. Evid Based Complement Alternat Med (2013) 0.76
Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy. Autophagy (2015) 0.76
Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels. Oncotarget (2016) 0.75
Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. Int J Mol Sci (2017) 0.75
Polymeric nanoparticle-based delivery of TRAIL DNA for cancer-specific killing. Bioeng Transl Med (2016) 0.75
PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. Oncotarget (2017) 0.75
The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death. J Biol Chem (2016) 0.75
Reversal of the Apoptotic Resistance of Non-Small-Cell Lung Carcinoma towards TRAIL by Natural Product Toosendanin. Sci Rep (2017) 0.75
Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation. Cell Death Dis (2016) 0.75
Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway. J Immunol (2014) 0.75
SmacN7 enhances the sensitivity of pancreatic cancer cells to tumor necrosis factor-related apoptosis-inducing ligand or gemcitabine. Oncol Lett (2013) 0.75
Methanolic extract of white asparagus shoots activates TRAIL apoptotic death pathway in human cancer cells and inhibits colon carcinogenesis in a preclinical model. Int J Oncol (2013) 0.75
Functional Detection of TNF Receptor Family Members by Affinity-Labeled Ligands. Sci Rep (2017) 0.75
HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression. Oncotarget (2017) 0.75
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (2007) 20.11
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell (2007) 6.68
Overview of cell death signaling pathways. Cancer Biol Ther (2005) 4.22
Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature (2007) 4.14
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Critical role for Daxx in regulating Mdm2. Nat Cell Biol (2006) 2.96
TRAIL and apoptosis induction by TNF-family death receptors. Oncogene (2003) 2.75
P53 and radiation responses. Oncogene (2003) 2.52
Retracted GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol Cell (2009) 2.30
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med (2013) 2.06
p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol (2013) 2.06
Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther (2003) 1.92
The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther (2002) 1.91
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol (2006) 1.88
BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol (2002) 1.84
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol (2003) 1.83
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A (2006) 1.80
Tissue-specific induction of p53 targets in vivo. Cancer Res (2002) 1.79
A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science (2011) 1.79
BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol Ther (2002) 1.72
TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets (2010) 1.65
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res (2007) 1.58
CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. Curr Biol (2008) 1.58
DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol (2005) 1.55
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell (2004) 1.54
Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol (2003) 1.54
Restoration of p53 to limit tumor growth. Curr Opin Oncol (2008) 1.52
The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle (2002) 1.45
Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget (2011) 1.43
Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther (2009) 1.43
TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest (2008) 1.41
Mcl-1: a gateway to TRAIL sensitization. Cancer Res (2008) 1.41
Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis (2009) 1.40
Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther (2005) 1.38
Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol Ther (2004) 1.38
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther (2008) 1.34
Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol Ther (2003) 1.32
Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. Radiat Res (2009) 1.31
Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci U S A (2002) 1.30
Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem (2004) 1.29
Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res (2004) 1.28
BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol (2002) 1.28
Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle (2007) 1.28
Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol (2005) 1.27
Current strategies to target p53 in cancer. Biochem Pharmacol (2010) 1.26
Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol (2008) 1.25
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol (2003) 1.25
Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia (2002) 1.24
Restoring p53-dependent tumor suppression. Cancer Biol Ther (2003) 1.24
Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem (2011) 1.23
Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res (2004) 1.22
An integrated, multiparametric flow cytometry chip using "microfluidic drifting" based three-dimensional hydrodynamic focusing. Biomicrofluidics (2012) 1.22
Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther (2007) 1.22
Circulating Tumor Cells and Colorectal Cancer. Curr Colorectal Cancer Rep (2010) 1.21
Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res (2006) 1.20
The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle (2009) 1.18
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest (2014) 1.16
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A (2003) 1.16
Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther (2006) 1.16
What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biol Ther (2006) 1.16
Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J Clin Oncol (2011) 1.15
ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle (2015) 1.14
Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet (2003) 1.14
Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis (2003) 1.13
Regulation of the human TRAIL gene. Cancer Biol Ther (2012) 1.12
Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle (2002) 1.12
Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci U S A (2004) 1.10
p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res (2006) 1.09
Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol (2008) 1.08
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle (2011) 1.07
Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol Ther (2005) 1.04
ERK and MDM2 prey on FOXO3a. Nat Cell Biol (2008) 1.04
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther (2013) 1.03
Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res (2013) 1.02
Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther (2005) 1.02
Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol (2004) 1.02